Home
contact us  /  email
about us
portfolio
team
news
Jun 26, 2016
Coherus BioSciences advances differentiated IP strategy for Humira market access
GLOBE NEWSWIRE
REDWOOD CITY, Calif., May 26, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that the United States Patent and Trademark Office (USPTO) issued to Coherus U.S. Patents 9,340,611; 9,340,612 and 9,346,880. These patents generally concern formulations of adalimumab, the active biological ingredient in Coherus’ Humira biosimilar, CHS-1420, currently in Phase 3.   more >>
May 23, 2016
Coherus Prices Public Offering of the Common Stock
GLOBE NEWSWIRE
REDWOOD CITY, Calif., May 23, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced the pricing of its underwritten public offering of 3,500,000 shares of its common stock at a price to the public of $18.00 per share.   more >>
May 17, 2016
Coherus BioSciences Provides Update on ‘135 IPR
GLOBE NEWSWIRE
REDWOOD CITY, Calif., May 17, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it has received a favorable decision from the Patent Trial and Appeal Board (“PTAB”) of the US Patent and Trademark office instituting Coherus’ petition for Inter Partes Review (“IPR”) of AbbVie’s U.S. Patent 8,889,135   more >>
Jul 29, 2014
Proteus Digital Health™ Continues to Build Momentum, Most Recent Round of Funding Reaches over $172MM
Proteus Digital Health, Inc., Redwood City, California
Proteus Digital Health, Inc., the leading digital medicines company, today announced that it has completed a second closing of its Series G financing, raising over $172 million and adding additional respected institutional investors.   more >>
Mar 04, 2014
Invuity® Raises $36 Million in Series E Financing
Invuity, Inc., San Francisco, California
Invuity, Inc., a developer of advanced medical devices to dramatically improve access and visualization in minimally invasive and minimal access surgeries, announced today that it has secured $36 million in a Series E financing led by HealthCare Royalty Partners (“HC Royalty”), along with existing investors Valence Life Sciences, InterWest Partners, Kleiner Perkins Caufield and Byers, and a number of other qualified investors.   more >>
Sep 03, 2013
Baxter and Coherus Biosciences Announce Collaboration to Develop and Commercialize Biosimilars
Baxter International, Deerfield, Illinois, and Coherus Biosciences, Redwood City, California
Baxter International Inc. (NYSE:BAX) and Coherus Biosciences, Inc. today announced that they have entered into an exclusive collaboration to develop and commercialize a biosimilar to etanercept   more >>
Aug 08, 2013
The pill that texts the doctor - from inside your body
BBC News, UK
Fiona Graham, technology of business reporter, BBC News, explores therapeutic and economic benefits of the Proteus Digital health platform   more >>
Jul 26, 2013
Soldiers, Athletes Watched from Inside by Tiny Pill
Bloomberg, USA
Bloomberg TV takes a look at the emerging market of ingestible electronics, including technologies developed by Proteus Digital Health   more >>
Apr 18, 2013
Novation to Offer Invuity® Products to 65,000 Member Hospitals and Affiliates
Invuity, Inc., San Francisco, California
Group Purchasing Agreement Optimizes Invuity’s Sales Force to Support Rapid Multi-Specialty Adoption of EigrTM Illumination Technology   more >>
Jul 24, 2012
Chimerix Signs Worldwide License Agreement with Merck for CMX157, A Novel Candidate for the Treatment of HIV
Chimerix, Inc., Triangle Park, North Carolina
Chimerix, Inc. announced the execution of a license agreement granting Merck exclusive worldwide rights to CMX157, novel lipid acyclic nucleoside phosphonate currently being evaluated to treat HIV infection.   more >>
Jul 23, 2012
CMX001 Demonstrates Potential to Mitigate BK Virus Associated End-organ Disease in Clinical Study
Chimerix, Inc., Triangle Park, North Carolina
Chimerix, Inc. presented that its lead antiviral compound, CMX001, has the potential to reduce end-organ damage associated with BK virus (BKV) in hematopoietic stem cell transplant (HSCT) recipients   more >>
Jul 05, 2012
Proteus Digital Health, Inc. and Otsuka Pharmaceutical Co., Ltd. Announce Worldwide Agreement to Develop Novel Digital Health Products
Proteus Digital Health, Redwood City, California and Otsuka Pharmaceutical Co., Tokyo, Japan
Proteus Digital Health, Inc. and Otsuka Pharmaceutical Co., Ltd. announced they have entered into an exclusive worldwide license and collaboration agreement to develop and commercialize a new category of medicines.   more >>
Jun 14, 2012
Invuity Raises $25 Million in Series D Funding
Invuity, San Francisco, California
Invuity, a leading developer of state-of-the-art surgical visualization and illumination technology, has raised a $25 million Series D round of financing   more >>
May 10, 2012
Coherus Biosciences and Daiichi Sankyo Establish Strategic Collaboration to Develop and Commercialize Biosimilar Candidates
Coherus Biosciences, Redwood City, USA
Coherus BioSciences, Inc. and Daiichi Sankyo, Co. Ltd. announced the execution of an exclusive agreement to develop and commercialize biosimilar forms of etanercept and rituximab in certain Asian countries including Japan   more >>
Oct 26, 2011
Invuity Introduces Advanced Illuminated Surgical System for Breast Procedures
FierceMedicalDevices, USA
Invuity, a leading developer of state-of-the-art illuminated surgical technology, today introduced its illuminated breast retractor system at the American College of Surgeons' 97th Annual Clinical Congress in San Francisco   more >>
Oct 18, 2011
iScience Interventional Announces Clinical and Commercial Supply Agreement
iScience Interventional, Menlo Park, CA
iScience Interventional pioneers of site-specific therapies for anterior and posterior ocular diseases, today announced it has signed a clinical and commercial supply agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD) and its affiliates.   more >>
Feb 16, 2011
Chimerix Awarded BARDA Contract for Advanced Development of Antiviral CMX001 as Medical Countermeasure Against Smallpox
Chimerix, Inc., Durham, North Carolina
Chimerix, Inc. has been awarded a contract that will finance the smallpox drug development with committed funding of $24.8 million during the first year and subsequent option to bring the total contract value to $81.1 million.   more >>
Feb 11, 2011
Sonoma Orthopedic Products® Announces Acquisition of Key NovaLignTM Orthopaedics, Inc. Assets
Sonoma Orthopedic Products, Inc., Santa Rosa, California
Sonoma Orthopedic Products announced that it has completed the acquisition of certain key assets of NovaLign Orthopaedics, Inc.   more >>
Apr 09, 2010
Innovation, by Order of the Kremlin
The New York Times, New York, United States
Dr. Evgeny Zaytsev answers questions by Andrew Kramer, The New York Times correspondent, on the Russian initiative to build an   more >>
Mar 09, 2010
Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus.
Chimerix, Inc., Durham, North Carolina
Chimerix announces a multi-center Phase 2 clinical trial designed to evaluate CMX001 in stem cell transplant recipients seropositive for cytomegalovirus (CMV).   more >>
Jan 14, 2010
Pills Get Smart. Potential Encapsulated.
Economist, New York, United States
Article about the business potential of just announced licensing deal between Proteus Biomedical and Novartis.   more >>
Sep 29, 2009
InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study of Diabetes Meeting
InteKrin Therapeutics, Los Altos, California
InteKrin announces positive safety data for for a new Type 2 Diabetes treatment.   more >>
Sep 29, 2009
InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
InteKrin Therapeutics, Los Altos, California
InteKrin announces positive Phase IIb data for a new Type 2 Diabetes treatment with superior safety profile.   more >>
Sep 20, 2009
Novartis chip to help ensure bitter pills are swallowed
Financial Times, London, UK
Article on possible Novartis collaboration with Proteus Biomedical to improve patient adherence.   more >>
Aug 26, 2009
Asset Management Spinoff Helix Ventures Raising $150M Debut Fund
VentureWire, United States
Article by DowJones reporter Brian Gormley about formation of Helix Ventures.   more >>
Aug 03, 2009
Take Two Digital Pills and Call Me in the Morning
The Wall Street Journal, United States
WSJ reporter Don Clark presents Proteus Biomedical’s intelligent medicine platform.   more >>
Jul 15, 2009
BSI-201 Enters Phase 3 in Metastatic Triple Negative Breast Cancer
BiPar Sciences, Paris, France/South San Francisco, California
Recruitment Into Pivotal Phase 3 Study Initiated Just 2 Months After announcing positive Phase 2 Results.   more >>
Jun 15, 2009
CMX001 a Broad Spectrum Antiviral Drug for the Treatment of Smallpox
Chimerix, Inc., Durham, North Carolina
Chimerix’ presentation at the 7th Annual Biodefense Vaccines and Therapeutics Meeting.   more >>
May 30, 2009
New breast cancer drugs block cell repair enzyme
Reuters, United States
BiPar Sciences presents positive Phase II data at the annual meeting of the American Society of Clinical Oncology meeting.   more >>
May 18, 2009
Emergency IND granted for the use of CMX001 to treat complications following smallpox vaccination
CDC, Atlanta, United States
CMX001, a drug developed by Chimerix, Inc. proves effective in an emergency case.   more >>
May 12, 2009
Canaloplasty 2-year clinical results published
Ophthalmology Times, United States
iScience Interventional’s 2-year data confirm sustained eye pressure drop.   more >>
Apr 15, 2009
BiPar Buyout Proves VC Model Can Work
The Wall Street Journal, United States
WSJ reporter Brian Gormley interviews Dr. Graham Crooke on the BiPar investment model.   more >>
Apr 14, 2009
Sanofi-aventis to acquire BiPar Sciences, a US biopharmaceutical company
Sanofi-Aventis, Paris, France
Sanofi-aventis announces acquisition of BiPar for $500 million in a staged cash transaction.   more >>
Jan 05, 2009
Chimerix completes Phase I study and initiates a Phase II multi-dose clinical trial for CMX001
Chimerix, Inc., Durham, North Carolina
Chimerix reports positive results of the Phase I clinical study in healthy volunteers.   more >>
Dec 03, 2008
Proteus Biomedical Honored by World Economic Forum
Proteus Biomedical, Inc., Redwood City, California
Technology Pioneer Award Recognizes Potential of Intelligent Medicine to Improve Business and Society.   more >>
Oct 27, 2008
Sonoma Orthopedic Products Gets FDA OK for Clavicle Device
Orthopedics, Wayne, Pennsylvania
Sonoma Orthopedics announces FDA clearance to use Sonoma technology to fix clavicle fractures.   more >>
Jun 10, 2008
Novare Surgical Wins Medical Design Excellence Award
Novare Surgical, Cupertino, California
RealHand® High Dexterity (HD) instruments by Novare recognized in premier program for the medical technology community.   more >>
Jun 08, 2008
A nervy approach to weight loss
Los Angeles Times, Los Angeles, California
Article about the benefits of vagotomy procedure developed by EndoVx for obese patients.   more >>
May 29, 2006
MicroVention and Terumo Corporation Announce Completion of Merger
MicroVention, Inc., Aliso Viejo, California
MicroVention announces the completion of the merger with Terumo Corporation (Japan).   more >>
Apr 17, 2005
Boston Scientific Announces Acquisition of TriVascular, Inc.
Boston Scientific Corporation, Natick, Massachusetts
Press release by Boston Scientific announcing TriVascular acquisition.   more >>
Sep 22, 2003
Chimerix Awarded $36.1M NIH Grant
Chimerix, Inc., San Diego, California
Chimerix Awarded $36.1M NIH Grant to Develop it's Oral Drug for the Treatment of Smallpox Infection.   more >>
Jul 02, 2002
Company agrees to acquire Enteric Medical Technologies
Biotech Week, United States
Boston Scientific announcesthe acquisition of Enteric Medical Technologies.   more >>
Feb 26, 2002
Baxter Signs Agreement to Acquire Fusion
Baxter International, Deerfield, Illinois; Fusion Medical Technologies, Inc., Fremont, California
Baxter International and Fusion Medical Technologies, Inc. jointly announce an acquisition agreement.   more >>
<< Back to news

 
 
© Helix Ventures 2008 – 2015   /   about us   /   portfolio   /   team   /   news   /   contact us